Second part of Belopenem formulation work is initiated

Double Bond Pharmaceutical has now initiated the second part of formulation work for Belopenem project. In this part the targeting effect of a number of formulation that passed all the analytical criteria in part one will be tested in vivo and the best one will be further selected and developed as a new medicine. Belopenem is a combination of meropenem, which is a well-known antibiotic against pneumonia, and DBP’s own platform Belogal® that targets the active substance to the selected organ, in this very case to the lung.

“We are very satisfied with being able to keep the timeline and successfully initiate the second step virtually immediately after the completion of the first one, - Igor Lokot, CEO at Double Bond Pharmaceutical, comments. - ”Now it is time to identify the targeting grade of Belopenem formulations, i.e. to find out how effectively and to what extent can we target the active substance meropenem to the lung.”

More about Belopenem project: /mbpublicbinaryproxy/Main/12720/2576018/878966.pdf 

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 27 of March 2019. 

Full Company Name:  Double Bond Pharmaceutical International AB (publ)
Corporate identity:     556991-6082
Stock short name:      DBP B
Share ISIN code:         SE0007185525 

For more info, contact
Igor Lokot, CEO




Follow us on LinkedIn, Facebook and Twitter!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.



Documents & Links